ABL503
HomePipelineABL503
-
- Pipeline
- ABL503
-
- Program Target
- PD-L1 x 4-1BB
-
- Disease Indication
- Solid Tumor
-
- Development Stage
- Clinical Development
(Phase 1)
- Summary
-
ABL503 is a bispecific antibody that combines the capabilities of PD-L1 checkpoint pathway
inhibiton with 4-1BB agonistic activity to overcome the specific limitations of PD-(L)1
immunotherapy and 4-1BB related toxicity. ABL503 is uniquely designed to only induce 4-1BB
signalling when simultaneously binded to the PD-L1 tumor antigen on cancer cells, limiting the
toxicity characteristic of traditional 4-1BB based treatment while augmenting T-cell activation.
ABL503 shows superior anti-tumor activity in an animal model system compared to PD-L1
alone, 4-1BB alone, and the combination of PD-L1 and 4-1BB, with immunological memory
resistant to any possible recurrence of the tumor.
Structure and Mechanism of Action
PD-L1 Dependent 4-1BB Activation
Superior Anti-Tumor Effect with Immunological Memory
Pharmacodynamic changes along with anti-tumor effect
Superior activity over Atezolizumab
Publications
Posters